Evidence map›Paper›PMID 38382182›Full record

ReviewClinical medicine (London, England)2024

Pulmonary endemic mycoses.

Michael J Wilson, Irasha Harding, Andrew M Borman, Elizabeth Johnson, Robert Miller

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical medicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Treat staff like they make a difference, and they will.Clinical medicine (London, England) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael J WilsonSpR in infectious diseases and microbiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. Electronic address: michael.wilson@uhbw.nhs.uk.
Irasha Hardingconsultant microbiologist, National Infection Service, Bristol, UK.
Andrew M Bormandeputy director, UKHSA National Mycology Reference Laboratory, Bristol, UK; honorary professor of medical mycology, University of Exeter, Exeter, UK.
Elizabeth Johnsonhonorary professor of medical mycology, University of Exeter, Exeter, UK; director, UKHSA National Mycology Reference Laboratory, Bristol, UK.
Robert MillerAssociate Professor of Clinical Infection, Institute for Global Health, University College London.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While rare, the likelihood of encountering a case of a pulmonary endemic mycosis (PEM) in the UK is increasing. Diagnosis may be challenging, often leading to considerable delay to appropriate treatment. Clinical suspicion must be present for respiratory disease, particularly in the immunocompromised or in those not responding to empiric treatment approaches, and an extended travel history should be obtained. This article summarises the epidemiology of PEM, key clinical features, diagnostic strategies and management.

Indexed as

Lung Diseases, FungalMycosesHumansImmunocompromised HostEndemic mycosesFungiImmunocompromisedInfectionPulmonary

Identifiers

PMID38382182
PMCPMC11024832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.